RET is expressed but not mutated in extra-adrenal paragangliomas

Journal of Pathology

Volumn 191, Issue 3, 2000, Pages 264-268

  Krijger, Ronald R de ^a   Harst, Erwin van der ^a   Muletta Feurer, Seraina ^b   Bruining, Hajo A ^a   Lamberts, Steven W J ^a   Dinjens, Winand N M ^a   Roth, Jürgen ^b   Heitz, Philipp U ^b   Komminoth, Paul ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

MEN 2; Mutation analysis; Paraganglioma; RET proto oncogene

Indexed keywords

ADULT; ARTICLE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE ENDOCRINE NEOPLASIA; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POINT MUTATION; PRIORITY JOURNAL; PROTO ONCOGENE; THYROID MEDULLARY CARCINOMA;

ADULT; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DROSOPHILA PROTEINS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PARAGANGLIOMA, EXTRA-ADRENAL; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 0033921316     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH638>3.0.CO;2-I     Document Type: Article

References (29)

1. Le Douarin NM. The ontogeny of the neural crest in avian embryo chimeras. Nature 1980; 286: 663-669.
2. Van der Mey AGL. Head and neck paragangliomas. Thesis, Leiden University, 1992.
3. Oosterwijk JC, Jansen JC, Schothorst EM van, et al. First experiences with genetic counselling based on predictive DNA diagnosis in hereditary glomus tumours (paragangliomas). J Med Genet 1996; 33: 379-383.
4. Gufferman S, Gillman MW, Paternak LR, Peterson CL, Young WG. Familial carotid body tumors: case study and epidemiologic review. Cancer 1980; 46: 2116-2122.
5. Nakamura T, Ishizaka Y, Nagao M, Hara M, Ishikawa T. Expression of the ret proto-oncogene product in human normal and neoplastic tissues of neural crest origin. J Pathol 1994; 172: 255-260.
6. Ponder BAJ. The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome. Cancer Res (Suppl) 1999; 59: 1736s-1742s.
7. Hofstra RMW, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994; 367: 375-376.
8. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. J Am Med Assoc 1996; 276: 1575-1579.
9. Eng C, Mulligan LM. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease. Hum Mutat 1997; 9: 97-109.
10. Harst E van der, Krijger RR de, Bruining HA, et al. Prognostic value of RET proto-oncogene point mutations in malignant and benign, sporadic phaeochromocytomas. Int J Cancer 1998; 79: 537-540.
11. Lindor NM, Honchel R, Khosla S, Thibodeau SN. Mutations in the RET protooncogene in sporadic pheochromocytomas. J Clin Endocrinol Metab 1995; 80: 627-629.
12. Beldjord C, Desclaux-Arramond F, Raffin-Sanson M, et al. The RET protooncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects. J Clin Endocrinol Metab 1995; 80: 2063-2068.
13. Zedenius J, Larsson C, Bergholm U, et al. Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 1995; 80: 3088-3090.
14. Romei C, Elisei R, Pinchera A, et al. Somatic mutations of the ret proto-oncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 1996; 81: 1619-1622.
15. Norton JA, Froome LC, Farell RE. Multiple endocrine neoplasia type 2B: the most aggressive form of medullary thyroid carcinoma. Surg Clin North Am 1979; 59: 109-118.
16. Komminoth P, Roth J, Muletta-Feurer S, Saremaslani P, Seelentag WKF, Heitz PhU. RET proto-oncogene point mutations in sporadic neuroendocrine tumors. J Clin Endocrinol Metab 1996; 81: 2041-2046.
17. Komminoth P, Kunz EK, Hiort O, et al. Analysis of RET proto-oncogene point mutations allows for the discrimination of heritable and non-heritable medullary thyroid carcinoma. Cancer 1995; 76: 479-489.
18. Komminoth P, Kunz E, Hiort O, et al. Detection of RET proto-oncogene point mutations in paraffin-embedded pheochromocytoma specimens by non-radioactive single strand conformation polymorphism analysis and direct sequencing. Am J Pathol 1994; 145: 922-929.
19. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory Press: New York, 1989.
20. Williams GH, Rooney S, Carss A, Cummins G, Thomas GA, Williams ED. Analysis of the RET proto-oncogene in sporadic parathyroid adenomas. J Pathol 1996; 180: 138-141.
21. Carlson KM, Dou S, Chi D, et al. Single missense mutation in the tyrosine kinase catalytic domain of the ret protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A 1994; 91: 1579-1583.
22. Yoshimoto K, Tanaka C, Hamaguchi S, et al. Tumor-specific mutations in the tyrosine kinase domain of the RET proto-oncogene in pheochromocytoma of sporadic type. Endocrine J 1995; 42: 265-270.
23. Eng C, Crossey PA, Mulligan L, et al. Mutations in the RET protooncogene and the von Hippel-Lindau disease tumor suppressor gene in sporadic and syndromic pheochromocytomas. J Med Genet 1995; 32: 934-937.
24. Rodien P, Jeunemaitre X, Dumont C, Beldjord C, Plouin PF. Genetic alterations of the RET proto-oncogene in familial and sporadic pheochromocytomas. Harm Res 1997; 47: 263-268.
25. Hofstra RMW, Stelwagen T, Stulp RP, et al. Extensive mutation scanning of RET in sporadic medullary thyroid carcinoma and of RET and VHL in sporadic pheochromocytoma reveals involvement of these genes in only a minority of cases. J Clin Endocrinol Metab 1996; 81: 2881-2884.
26. Van der Mey AGL, Maaswinkel-Mooy PD, Cornelisse CJ, Schmidt PH, Van de Kamp JJP. Genomic imprinting in hereditary glomus tumours: evidence for new genetic theory. Lancet 1989; ii: 1291-1294.
27. Heutink P, Van der Mey AGL, Sandkuijl L, et al. A gene subject to genomic imprinting and responsible for hereditary paragan-gliomas maps to chromosome 11q23-qter. Hum Mol Genet 1992; 1: 7-10.
28. Wang DG, Barros D'Sa AAB, Johnston CF, Buchanan KD. Oncogene expression in carotid body tumors. Cancer 1996; 77: 2581-2587.
29. Vargas MP, Zhuang Z, Wang C, Vortmeyer A, Linehan WM, Merino MJ. Loss of heterozygosity on the short arm of chromosomes 1 and 3 in sporadic pheochromocytoma and extra-adrenal paraganglioma. Hum Pathol 1997; 28: 411-415.